{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T21:38:03Z","timestamp":1761946683415,"version":"3.30.0"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":5356,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,1]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>l\u2013FMAU [1\u2013(2\u2013fluoro\u20135\u2013methyl\u2013\u03b2,l\u2013arabinofuranosyl) uracil] has been shown to be an effective inhibitor of hepatitis B virus (HBV) and duck hepatitis B virus replication in cell culture and duck hepatitis B virus replication in acutely infected Peking ducks. The woodchuck hepatitis virus (WHV) and its natural host, the Eastern woodchuck (<jats:italic toggle=\"yes\">Marmota monax<\/jats:italic>), have been established as a predictive model for the evaluation of antiviral therapies against chronic HBV infection. In this report, the antiviral activity of l\u2013FMAU against WHV replication in chronically infected woodchucks is described. Four weeks of once\u2013daily oral administration of l\u2013FMAU significantly reduced viremia, antigenemia, intrahepatic WHV replication, and intrahepatic expression of woodchuck hepatitis virus core antigen (WHcAg) in a dose\u2013dependent manner. At the highest dose administered (10 mg\/kg\/d), significant reductions of intrahepatic WHV RNA and covalently closed circular (ccc)WHV\u2013DNA levels also were observed. The reduction in viremia was remarkably rapid at the higher doses of l\u2013FMAU, with greater than 1,000\u2013fold reductions in WHV\u2013DNA serum levels observed after as little as 2 to 3 days of therapy. Following the withdrawal of therapy, a dose\u2013related delay in viremia rebound was observed. At the highest doses used, viremia remained significantly suppressed in at least one half of the treated animals for 10 to 12 weeks' posttreatment. No evidence of drug\u2013related toxicity was observed in the treated animals. l\u2013FMAU is an exceptionally potent antihepadnaviral agent <jats:italic toggle=\"yes\">in vitro<\/jats:italic> and <jats:italic toggle=\"yes\">in vivo<\/jats:italic>, and is a suitable candidate for antiviral therapy of chronic HBV infection.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1053\/jhep.2001.20899","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T03:46:10Z","timestamp":1030247170000},"page":"254-266","update-policy":"http:\/\/dx.doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":110,"title":["Antiviral Activity of Clevudine [L\u2013Fmau, (1\u2013(2\u2013Fluoro\u20135\u2013Methyl\u2013\u03b2, L\u2013Arabinofuranosyl) Uracil)] Against Woodchuck Hepatitis Virus Replication and Gene Expression in Chronically Infected Woodchucks ( Marmota Monax )"],"prefix":"10.1097","volume":"33","author":[{"given":"Simon F.","family":"Peek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Cote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilia A.","family":"Toshkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William E.","family":"Hornbuckle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betty H.","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances V.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. K.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Gerin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bud C.","family":"Tennant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent E.","family":"Korba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1053%2Fjhep.2001.20899","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200101000-00033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T11:34:43Z","timestamp":1733052883000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200101000-00033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001]]}},"URL":"https:\/\/doi.org\/10.1053\/jhep.2001.20899","relation":{},"ISSN":["0270-9139"],"issn-type":[{"type":"print","value":"0270-9139"}],"subject":[],"published":{"date-parts":[[2001,1]]}}}